Stock Watch: Roche’s Long Shot Over Its Patent Cliff
Is Big Pharma Losing Its Defensive Investment Attributes?
The pharmaceutical sector has historically provided generalist fund managers with a defensive tilt to offset their more cyclical exposures. But the opening announcements of third-quarter earnings season may show this counterbalance is under threat.
You may also be interested in...
With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway
Johnson & Johnson investors are turning attention to 2023, when the company's top-selling drug is set to face biosimilar competition in the US for the first time.
Vabysmo Is Bright Spot For Roche In Bumpy Q3
Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.
Stock Watch: Orphan Drug Profitability Under Threat
The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?